Leaflet IRINOTECAN ACCORD 20mg / ml concentrate for solution for infusion


Indicated for: colorectal cancer

Substance: irinotecan (topoisomerase inhibitor)

ATC: L01CE02 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Topoisomerase 1 (TOP1) inhibitors)

Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.

The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.

Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.

Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.

General data about IRINOTECAN ACCORD 20mg / ml

  • Substance: irinotecan
  • Date of last drug list: 01-05-2026
  • Commercial code: W65797003
  • Concentration: 20mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 258.94 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
  • Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
  • Number: 9233/2016/03
  • Shelf life: 3 years

Concentrations available for irinotecan

  • 1.5mg/ml
  • 20mg/ml
  • 4.3mg/ml

Compensation lists for IRINOTECAN ACCORD 20mg / ml Accord

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

258.94 RON

258.94 RON

0.00 RON